NIAID/NIH Over the past 20 years, several coronaviruses have crossed the species barrier into humans, causing outbreaks of severe, and often fatal, respiratory illness.
0.708: (NIAID/NIH; have crossed the species barrier into; humans)
0.511: (NIAID/NIH; have crossed the species barrier; respiratory illness)
0.434: (several coronaviruses; be NIAID/NIH over; the past 20 years)
0.421: (NIAID/NIH; have crossed respiratory illness causing; outbreaks of severe)
0.421: (NIAID/NIH; have crossed the species barrier causing; outbreaks of severe)
0.397: (NIAID/NIH; have crossed respiratory illness into; humans)
0.395: (NIAID/NIH; have crossed respiratory illness; the species barrier)

Since SARSCoV was first identified in animal markets, global viromics projects have discovered thousands of coronavirus sequences in diverse animals and geographic regions.
0.836: (global viromics projects; have discovered; thousands of coronavirus sequences)

Unfortunately, there are few tools available to functionally test these novel viruses for their ability to infect humans, which has severely hampered efforts to predict the next zoonotic viral outbreak.
0.69: (these novel viruses; to be functionally test for; their ability to infect humans ,)

Here we developed an approach to rapidly screen lineage B betacoronaviruses, such as SARS-CoV and the recent 2019-nCoV, for receptor usage and their ability to infect cell types from different species.
0.717: (we; Here developed; an approach to rapidly screen lineage B betacoronaviruses , such as SARS-CoV and the recent 2019-nCoV)
0.708: (cell types; to be infect from; different species)
0.559: (we; Here developed an approach to rapidly screen lineage B betacoronaviruses , such as SARS-CoV and the recent 2019-nCoV for; receptor usage)
0.557: (an approach to rapidly screen lineage B betacoronaviruses , such as SARS-CoV and the recent 2019-nCoV; be Here developed for; receptor usage)

We show that host protease processing during viral entry is a significant barrier for several lineage B viruses and that bypassing this barrier allows several lineage B viruses to enter human cells through an unknown receptor.
0.835: (host protease processing; is a significant barrier for; several lineage B viruses)[attrib=We show]
0.731: (B; viruses to enter human cells through; an unknown receptor)
0.708: (human cells; to be enter through; an unknown receptor)
0.66: (B; viruses to enter; human cells)
0.634: (host protease processing; is; a significant barrier)
0.632: (host protease processing; allows; several lineage B viruses to enter human cells through an unknown receptor)[attrib=We show]
0.351: (a significant barrier; be host protease processing during; viral entry)

We also demonstrate how different lineage B viruses can recombine to gain entry into human cells and confirm that human ACE2 is the receptor for the recently emerging 2019-nCoV.
0.818: (human ACE2; is the receptor for; the recently emerging 2019-nCoV)[attrib=We confirm]
0.798: (different lineage B viruses; can recombine to gain; entry)[attrib=We also demonstrate]
0.549: (human ACE2; is; the receptor)

Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) first emerged in humans in 2003 after transmitting from animals in open air markets in China1,2.
0.908: (Severe Acute Respiratory Syndrome Coronavirus; first emerged in; 2003)
0.908: (Severe Acute Respiratory Syndrome Coronavirus; first emerged in; humans)

Shortly thereafter, several genetically related viruses were identified in Chinese Horseshoes bats (Rhinolophus sinicus)3-7.
0.869: (several genetically related viruses; Shortly thereafter were identified in; Chinese Horseshoes bats)

At the same time, improvements in next generation sequencing technology lead to a boom of virus discovery, uncovering thousands of novel virus sequences in wild animal populations around the world.
0.696: (technology lead; be sequencing to; a boom of virus discovery)
0.65: (next generation; sequencing technology lead to; a boom of virus discovery)

While most of these viruses have never been found in humans, many are genetically similar to known human viruses within the betacoronaviruses (¦Â-CoV) genus.
0.844: (many; are genetically similar to; known human viruses)[enabler=While most of these viruses have never been found in humans]
0.697: (most of these viruses; have never been found in; humans)

The ¦Â-CoVs are further divided into four lineages: lineage B, which includes SARS-CoV and the newly emerging 2019-nCoV, has approximately 200 published virus sequences whereas lineage C, which includes MERSCoV, has over 500 viral sequences.
0.919: (The ¦Â-CoVs; are further divided into; four lineages)
0.889: (lineage B; published virus sequences whereas; lineage C which includes MERSCoV , has over 500 viral sequences)
0.829: (virus sequences; be published whereas; lineage C which includes MERSCoV , has over 500 viral sequences)
0.743: (lineage B; published; virus sequences)
0.698: (MERSCoV; has; over 500 viral sequences)
0.407: (SARS-CoV and the newly emerging; be includes by; lineage B)

Every year, additional novel CoV sequences are discovered.
0.658: (additional novel CoV sequences; are discovered in; Every year)

However, there is a massive knowledge gap in the field as very little work is performed after the viral sequences are published.
No extractions found.

Therefore, it is unknown whether these novel viruses have the potential to emerge in human populations.
0.693: (these novel viruses; have; the potential)
0.63: (it; Therefore is; unknown)

Current methods for studying novel ¦Â-CoVs are technically demanding.
No extractions found.

Viral isolation from field samples is rarely successful and reverse genetics recovery of recombinant virus is labor-intensive, and expensive as synthesis of a single genome can cost upwards of $15,000.
0.795: (Viral isolation; is rarely; successful and reverse genetics recovery of recombinant virus is labor-intensive , and expensive)
0.754: (Viral isolation; is; successful and reverse genetics recovery of recombinant virus is labor-intensive , and expensive)
0.536: (reverse genetics recovery of recombinant virus; be expensive as; synthesis of a single genome)
0.382: (Viral isolation; be expensive as; synthesis of a single genome)
0.372: (successful and reverse genetics recovery of recombinant virus is labor-intensive , and expensive; be Viral isolation from; field samples)

These limitations are prohibitive to studying novel CoVs at the scale in which they are discovered.
0.726: (they; are discovered in; the scale)
0.675: (novel CoVs; be studying at; the scale in which they are discovered)

Cell entry is an essential component of cross-species transmission, especially for the ¦Â-CoVs.
0.908: (Cell entry; is an essential component of; cross-species transmission)
0.888: (Cell entry; is an essential component of cross-species transmission for; the ¦Â-CoVs)
0.724: (Cell entry; is; an essential component of cross-species transmission)
0.504: (essential; is component of cross-species transmission for; the ¦Â-CoVs)
0.496: (essential; is component of; cross-species transmission)

All CoVs encode a surface glycoprotein, spike, which binds to the host-cell receptor and mediates viral entry8.
0.841: (All CoVs; encode; a surface glycoprotein which binds to the host-cell receptor and mediates viral entry8)
0.775: (a surface glycoprotein; binds to; the host-cell receptor and mediates viral entry8)

For ¦Â-CoVs, a single region of the spike protein called the receptor binding domain (RBD) mediates the interaction with the host cell receptor.
0.767: (a single region of the spike protein; called; the receptor binding domain)
0.561: (the receptor binding domain; be called for; ¦Â-CoVs)
0.447: (a single region of the spike protein; called the receptor binding domain ( RBD ) mediates the interaction with the host cell receptor for; ¦Â-CoVs)
0.355: (single; be region of; the spike protein)

After binding the receptor, a nearby host protease cleaves the spike, which releases the spike fusion peptide, facilitating virus entry9-12.
0.797: (a nearby host protease; cleaves; the spike which releases the spike fusion peptide)
0.62: (the spike fusion peptide; be releases by; the spike)
0.401: (a nearby host protease; cleaves the spike , which releases the spike fusion peptide facilitating; virus entry9-12)

Known host receptors for ¦Â-CoVs include angiotensin converting enzyme 2 (ACE2) for SARS-CoV and dipeptidyl peptidase 4 (DPP4) for MERS-CoV13,14.
No extractions found.

Structural studies of coronaviruses have shown that the spike RBD is capable of folding independently from the rest of the spike protein and contains all of the structural information for host receptor binding15.
0.736: (the spike RBD; is; capable of folding independently from the rest of the spike protein and contains all of the structural information)
0.676: (the spike RBD; is capable of; the structural information)

Additionally, a previous study showed that replacing the RBD of the lineage B bat virus, Rp3, allowed the virus to enter cells expressing human ACE2 (hACE2)16.
0.767: (Rp3; allowed; the virus to enter cells)[attrib=a previous study Additionally showed]
0.516: (the RBD; be replacing of; the lineage B bat virus)

We therefore developed a method to functionally test the RBDs from novel lineage B ¦Â-CoVs in place of the SARS-CoV spike RBD (figure 1).
0.812: (We; therefore developed; a method to functionally test the RBDs from novel lineage B ¦Â-CoVs in place of the SARS-CoV spike RBD ( figure 1 ))
0.543: (the RBDs; to be functionally test from; novel lineage B ¦Â-CoVs)
0.54: (the RBDs; to be functionally test in; place of the SARS-CoV spike)

Synthesizing just the RBD of spike is much faster and cost-effective than conventional pseudotyping methods that rely on synthesis of the full ~4kb spike sequence for novel CoVs: a process that can take weeks and is cost-prohibitive for large panels of spike sequences.
0.811: (conventional pseudotyping methods; rely on; synthesis of the full ~4kb spike sequence)
0.405: (a process that can take weeks and is cost-prohibitive for large panels of spike sequences; Synthesizing; the RBD of spike)

The short turnaround time for our approach allowed us to test the receptor usage of all published, unique RBD sequences in lineage B, and also rapidly confirm the ACE2 receptor usage of the 2019-nCoV spike, which emerged in China in January 2020 as our study was ongoing.
0.798: (us; to test; the receptor usage of all published , unique RBD sequences)
0.757: (the 2019-nCoV spike; emerged in; January 2020)
0.74: (the 2019-nCoV spike; emerged in; China)
0.558: (the 2019-nCoV spike; emerged as; our study)
0.387: (us; to also rapidly confirm; the ACE2 receptor usage of the 2019-nCoV spike)

We show that lineage B RBDs divide into functionally distinct clades and that several previously-unappreciated viruses exhibit compatibility with an unknown receptor on human cells.
0.693: (several previously-unappreciated viruses; exhibit; compatibility)[attrib=We show]
0.681: (lineage B RBDs; divide into; distinct clades)[attrib=We show]
0.526: (several previously-unappreciated viruses; divide into; distinct clades)[attrib=We show]
0.516: (lineage B RBDs; exhibit; compatibility)[attrib=We show]

We also show that these clades are capable of recombining to impart human host-cell entry phenotypes, and that, beyond the RDB-receptor interaction, host protease processing is another species barrier encountered by lineage B ¦Â-CoVs during 293T, A549, BHK, Caco-2, Huh-7.5, PK-15, and Vero cells were maintained in DMEM (Sigma) supplemented with 10% FBS, penicillin/streptomycin, and L-glutamine.
0.761: (another species barrier encountered by lineage B ¦Â-CoVs during 293T , A549 , BHK , Caco-2 , Huh-7.5 , PK-15 , and Vero cells; were maintained in; DMEM)
0.748: (host protease processing; is; another species barrier encountered by lineage B ¦Â-CoVs during 293T , A549 , BHK , Caco-2 , Huh-7.5 , PK-15 , and Vero cells)
0.746: (host protease processing; is another species barrier beyond; the RDB-receptor interaction)
0.575: (penicillin/streptomycin; be supplemented with; 10 %)
0.541: (A549; be encountered during; 293T)

RhiNi/40.1,
No extractions found.

AJ-primary, AJi, HypNi, RaKSM-2.5i,
No extractions found.

RhiLu, and RhiNi cells were maintained in DMEM/F12 (Gibco) supplemented with 12% FBS, penicillin/streptomycin, nonessential amino acids, sodium pyruvate and L-glutamine.
0.885: (RhiLu , and RhiNi cells; were maintained in; DMEM/F12)
0.517: (penicillin/streptomycin; be supplemented with; 12 %)

AJ-primary cells were immortalized with a lentiviral vector expressing SV40 T-antigen following the manufacturer¡¯s instructions to generate AJi cells (abm; #G203).
0.9: (AJ-primary cells; were immortalized with; a lentiviral vector expressing SV40 T-antigen)

RaKSM-2.5 primary cells have been previously described and were immortalized in this study similar to AJi cells17.
0.876: (RaKSM-2.5 primary cells; have were immortalized in; this study similar)

The spike coding sequences for SARS-CoV Urbani, As6526, and BM48-31 were codon optimized for human cells, appended with a 5¡¯ kozak expression sequence (GCCACC) and 3¡¯ tetra-glycine linker followed by nucleotides encoding a FLAG tag sequence (DYKDDDDK).
0.706: (optimized; be appended with; a 5' kozak expression sequence)

For SARS-CoV spike, silent mutations were introduced around codons 308 and 519 to form KpnI and XhoI digest sites.
0.894: (silent mutations; were introduced around; codons 308)
0.762: (KpnI and XhoI; digest; sites)
0.738: (silent mutations; were introduced for; SARS-CoV spike)

For As6526 spike, silent mutations were introduced around codons 290 and 501 to form AflII and HindIII digest sites.
0.894: (silent mutations; were introduced around; codons 290)
0.754: (silent mutations; were introduced for; As6526 spike)
0.588: (AflII and HindIII; digest; sites)

For BM48-31 spike, silent mutations were introduced around codons 295 and 501 to form AflII and HindIII digest sites.
0.894: (silent mutations; were introduced around; codons 295)
0.742: (silent mutations; were introduced for; BM48-31 spike)
0.588: (AflII and HindIII; digest; sites)

These engineered spike sequences were synthesized and cloned into pcDNA3.1+
0.898: (These engineered spike sequences; be cloned into; pcDNA3.1+)

(GenScript).
No extractions found.

Spike RBDs were first codon-optimized for human cells, appended with regions of the target spike backbone to facilitate Infusion cloning and synthesized as double stranded DNA fragments (IDT DNA).
0.778: (Spike RBDs; were; first)

SARS-CoV, As6526 or BM48-31 engineered spike plasmids were digested with their corresponding restriction enzymes and gel purified.
0.742: (SARS-CoV , As6526 or BM48-31 engineered spike plasmids; were digested with; their corresponding restriction enzymes)

RBD inserts were resuspended in water and Infusion cloned into gel purified, digested spike backbone vectors (Takara).
0.914: (RBD inserts; were resuspended in; water and Infusion)
0.593: (digested spike backbone vectors; be cloned into; gel)

Human ACE2 (Q9BYF1.2),
No extractions found.

DPP4 (XM_005246371.3), or APN (NP_001141.2) were synthesized and cloned into pcDNA3.1+
No extractions found.

(GenScript).
No extractions found.

All DNA constructs were verified by Sanger sequencing (ACGT Inc.).
0.885: (All DNA constructs; were verified by; Sanger)

post-transfection.
No extractions found.

BHK cells were seeded in black 96-well plates and transfected the next day with 100ng plasmid DNA encoding human ACE2, DPP4, APN or empty vector, using polyethyleneimine (Polysciences).
0.835: (BHK cells; were seeded in; black 96-well plates)
0.652: (BHK cells; transfected with; 100ng plasmid DNA encoding human ACE2 , DPP4 , APN or empty vector)

All downstream experiments were performed 24 hours Pseudotypes were produced as previously described18.
No extractions found.

293T cells were seeded onto 6-well plates pre-coated with poly-L-lysine (Sigma) and transfected the next day with 1200ng empty plasmid and 400ng of plasmid encoding coronavirus spike or GFP as a no pseudotype control.
0.929: (293T cells; were seeded onto; 6-well plates pre-coated)

Twenty-four hours later, transfected cells were infected with VSV¦¤G particles pseudotyped with VSV-g as previously described19.
0.887: (transfected cells; Twenty-four hours later were infected with; VSV¦¤G particles)

After one hour of incubating at 37¡ãC, cells were washed three times and incubated in 2mL DMEM supplemented with 2% FBS, penicillin/streptomycin, and L-glutamine for 48 hours.
0.734: (cells; be incubated in; 2mL DMEM)
0.655: (cells; were washed three times after; one hour incubating at 37¡ãC)
0.518: (cells; were washed; three times)

Supernatants were collected, centrifuged at 500xG for 5 minutes, aliquoted and stored at -80.
No extractions found.

Target cells were seeded in black 96-well plates and inoculated, in triplicate, with equivalent volumes of pseudotype stocks.
0.894: (Target cells; were seeded in; black 96-well plates and inoculated)
0.894: (Target cells; were seeded in; triplicate)
0.853: (Target cells; were seeded with; equivalent volumes of pseudotype stocks)

For trypsin experiments, pseudotype stocks were diluted 1:1 in DMEM without FBS, trypsin was added to a final concentration of 2500¦Ìg/mL and samples were incubated at 37¡ãC for 15 minutes.
0.913: (pseudotype stocks; were diluted 1:1 in; DMEM)
0.847: (pseudotype stocks; were diluted 1:1 without; FBS)
0.806: (a final concentration of 2500¦Ìg/mL; to were incubated at; 37¡ãC)
0.781: (a final concentration of 2500¦Ìg/mL; to were incubated for; 15 minutes)
0.78: (pseudotype stocks; were diluted; 1:1)
0.754: (pseudotype stocks; were diluted 1:1 for; trypsin experiments)

Samples were then diluted again 1:1 in cold DMEM supplemented with 2% FBS and added to cells.
0.868: (1:1; supplemented with; 2 %)
0.702: (Samples; added to; cells)

Inoculated plates were centrifuged at 1200xG, 4¡ãC, for 1 hour and incubated over night at 37¡ãC.
0.894: (Inoculated plates; were centrifuged at; 1200xG)

Approximately 18-20 hours post-infection, Bright-Glo luciferase reagent (Promega) was added to each well, 1:1, without removing culture media and luciferase was measured.
0.861: (Bright-Glo luciferase reagent; Approximately 18-20 hours post-infection was added to; each well)

Relative entry was calculated by normalizing the relative light unit (RLU) for spike pseudotypes to the plate RLU average for the ¡°no pseudotype control.¡±
0.707: (the relative light unit; be normalizing to; the plate)
0.625: (the relative light unit; be normalizing rlu; average)
0.453: (the relative light unit; be normalizing for; the " no pseudotype control)

Producer cells (spike-transfected 293T) were lysed in 1%SDS, 150mM NaCl, 50mM Tris-HCl, 5mM EDTA and clarified by centrifugation at 14000xG for 20 minutes.
0.559: (150mM NaCl; were lysed in; 1 %SDS)
0.559: (50mM Tris-HCl; were lysed in; 1 %SDS)

Pseudotyped particles were concentrated from producer cell lysates that were overlaid a 10% OptiPrep cushion in PBS (Sigma) and centrifuged at 20,000¡Á g for 2 hours at 4 ¡ãC.
0.947: (Pseudotyped particles; were concentrated from; producer cell lysates that were overlaid a 10 % OptiPrep cushion in PBS ( Sigma ) and centrifuged at 20,000¡Á g for 2 hours at 4)

Lysates and concentrated particles were analyzed for FLAG, GAPDH and/or VSV-m expression on 10% Bis-Tris PAGE gel (ThermoFisher).
0.883: (Lysates and concentrated particles; were analyzed for; FLAG)

Accession numbers for all spike sequences used here can be found in figure s1b.
0.914: (Accession numbers; can be found in; figure s1b)

293T, A549, BHK, Caco-2, Huh-7.5, PK-15, and Vero cells were maintained in DMEM (Sigma) supplemented with 10% FBS, penicillin/streptomycin, and L-glutamine.
0.721: (293T , A549 , BHK , Caco-2 , Huh-7.5 , PK-15 , and Vero cells; were maintained in; DMEM)
0.575: (penicillin/streptomycin; be supplemented with; 10 %)

RhiNi/40.1,
No extractions found.

AJ-primary, AJi, HypNi, RaKSM-2.5i,
No extractions found.

RhiLu, and RhiNi cells were maintained in DMEM/F12 (Gibco) supplemented with 12% FBS, penicillin/streptomycin, nonessential amino acids, sodium pyruvate and L-glutamine.
0.885: (RhiLu , and RhiNi cells; were maintained in; DMEM/F12)
0.517: (penicillin/streptomycin; be supplemented with; 12 %)

AJ-primary cells were immortalized with a lentiviral vector expressing SV40 T-antigen following the manufacturer¡¯s instructions to generate AJi cells (abm; #G203).
0.9: (AJ-primary cells; were immortalized with; a lentiviral vector expressing SV40 T-antigen)

RaKSM-2.5 primary cells have been previously described and were immortalized in this study similar to AJi cells17.
0.876: (RaKSM-2.5 primary cells; have were immortalized in; this study similar)

The spike coding sequences for SARS-CoV Urbani, As6526, and BM48-31 were codon optimized for human cells, appended with a 5¡¯ kozak expression sequence (GCCACC) and 3¡¯ tetra-glycine linker followed by nucleotides encoding a FLAG tag sequence (DYKDDDDK).
0.706: (optimized; be appended with; a 5' kozak expression sequence)

For SARS-CoV spike, silent mutations were introduced around codons 308 and 519 to form KpnI and XhoI digest sites.
0.894: (silent mutations; were introduced around; codons 308)
0.762: (KpnI and XhoI; digest; sites)
0.738: (silent mutations; were introduced for; SARS-CoV spike)

For As6526 spike, silent mutations were introduced around codons 290 and 501 to form AflII and HindIII digest sites.
0.894: (silent mutations; were introduced around; codons 290)
0.754: (silent mutations; were introduced for; As6526 spike)
0.588: (AflII and HindIII; digest; sites)

For BM48-31 spike, silent mutations were introduced around codons 295 and 501 to form AflII and HindIII digest sites.
0.894: (silent mutations; were introduced around; codons 295)
0.742: (silent mutations; were introduced for; BM48-31 spike)
0.588: (AflII and HindIII; digest; sites)

These engineered spike sequences were synthesized and cloned into pcDNA3.1+
0.898: (These engineered spike sequences; be cloned into; pcDNA3.1+)

(GenScript).
No extractions found.

Spike RBDs were first codon-optimized for human cells, appended with regions of the target spike backbone to facilitate Infusion cloning and synthesized as double stranded DNA fragments (IDT DNA).
0.778: (Spike RBDs; were; first)

SARS-CoV, As6526 or BM48-31 engineered spike plasmids were digested with their corresponding restriction enzymes and gel purified.
0.742: (SARS-CoV , As6526 or BM48-31 engineered spike plasmids; were digested with; their corresponding restriction enzymes)

RBD inserts were resuspended in water and Infusion cloned into gel purified, digested spike backbone vectors (Takara).
0.914: (RBD inserts; were resuspended in; water and Infusion)
0.593: (digested spike backbone vectors; be cloned into; gel)

Human ACE2 (Q9BYF1.2),
No extractions found.

DPP4 (XM_005246371.3), or APN (NP_001141.2) were synthesized and cloned into pcDNA3.1+
No extractions found.

(GenScript).
No extractions found.

All DNA constructs were verified by Sanger sequencing (ACGT Inc.).
0.885: (All DNA constructs; were verified by; Sanger)

post-transfection.
No extractions found.

BHK cells were seeded in black 96-well plates and transfected the next day with 100ng plasmid DNA encoding human ACE2, DPP4, APN or empty vector, using polyethyleneimine (Polysciences).
0.835: (BHK cells; were seeded in; black 96-well plates)
0.652: (BHK cells; transfected with; 100ng plasmid DNA encoding human ACE2 , DPP4 , APN or empty vector)

All downstream experiments were performed 24 hours Pseudotypes were produced as previously described18.
No extractions found.

293T cells were seeded onto 6-well plates pre-coated with poly-L-lysine (Sigma) and transfected the next day with 1200ng empty plasmid and 400ng of plasmid encoding coronavirus spike or GFP as a no pseudotype control.
0.929: (293T cells; were seeded onto; 6-well plates pre-coated)

Twenty-four hours later, transfected cells were infected with VSV¦¤G particles pseudotyped with VSV-g as previously described19.
0.887: (transfected cells; Twenty-four hours later were infected with; VSV¦¤G particles)

After one hour of incubating at 37¡ãC, cells were washed three times and incubated in 2mL DMEM supplemented with 2% FBS, penicillin/streptomycin, and L-glutamine for 48 hours.
0.734: (cells; be incubated in; 2mL DMEM)
0.655: (cells; were washed three times after; one hour incubating at 37¡ãC)
0.518: (cells; were washed; three times)

Supernatants were collected, centrifuged at 500xG for 5 minutes, aliquoted and stored at -80.
No extractions found.

Target cells were seeded in black 96-well plates and inoculated, in triplicate, with equivalent volumes of pseudotype stocks.
0.894: (Target cells; were seeded in; black 96-well plates and inoculated)
0.894: (Target cells; were seeded in; triplicate)
0.853: (Target cells; were seeded with; equivalent volumes of pseudotype stocks)

For trypsin experiments, pseudotype stocks were diluted 1:1 in DMEM without FBS, trypsin was added to a final concentration of 2500¦Ìg/mL and samples were incubated at 37¡ãC for 15 minutes.
0.913: (pseudotype stocks; were diluted 1:1 in; DMEM)
0.847: (pseudotype stocks; were diluted 1:1 without; FBS)
0.806: (a final concentration of 2500¦Ìg/mL; to were incubated at; 37¡ãC)
0.781: (a final concentration of 2500¦Ìg/mL; to were incubated for; 15 minutes)
0.78: (pseudotype stocks; were diluted; 1:1)
0.754: (pseudotype stocks; were diluted 1:1 for; trypsin experiments)

Samples were then diluted again 1:1 in cold DMEM supplemented with 2% FBS and added to cells.
0.868: (1:1; supplemented with; 2 %)
0.702: (Samples; added to; cells)

Inoculated plates were centrifuged at 1200xG, 4¡ãC, for 1 hour and incubated over night at 37¡ãC.
0.894: (Inoculated plates; were centrifuged at; 1200xG)

Approximately 18-20 hours post-infection, Bright-Glo luciferase reagent (Promega) was added to each well, 1:1, without removing culture media and luciferase was measured.
0.861: (Bright-Glo luciferase reagent; Approximately 18-20 hours post-infection was added to; each well)

Relative entry was calculated by normalizing the relative light unit (RLU) for spike pseudotypes to the plate RLU average for the ¡°no pseudotype control.¡±
0.707: (the relative light unit; be normalizing to; the plate)
0.625: (the relative light unit; be normalizing rlu; average)
0.453: (the relative light unit; be normalizing for; the " no pseudotype control)

Producer cells (spike-transfected 293T) were lysed in 1%SDS, 150mM NaCl, 50mM Tris-HCl, 5mM EDTA and clarified by centrifugation at 14000xG for 20 minutes.
0.559: (150mM NaCl; were lysed in; 1 %SDS)
0.559: (50mM Tris-HCl; were lysed in; 1 %SDS)

Pseudotyped particles were concentrated from producer cell lysates that were overlaid a 10% OptiPrep cushion in PBS (Sigma) and centrifuged at 20,000¡Á g for 2 hours at 4 ¡ãC.
0.947: (Pseudotyped particles; were concentrated from; producer cell lysates that were overlaid a 10 % OptiPrep cushion in PBS ( Sigma ) and centrifuged at 20,000¡Á g for 2 hours at 4)

Lysates and concentrated particles were analyzed for FLAG, GAPDH and/or VSV-m expression on 10% Bis-Tris PAGE gel (ThermoFisher).
0.883: (Lysates and concentrated particles; were analyzed for; FLAG)

Accession numbers for all spike sequences used here can be found in figure s1b.
0.914: (Accession numbers; can be found in; figure s1b)

The receptor binding domain (RBD) of lineage B ¦Â-CoVs is a single, continuous domain that contains all structural information necessary to interact with the host receptor (figure 1a, b).
0.599: (all structural information necessary; be contains by; lineage B ¦Â-CoVs is a single , continuous domain)
0.55: (B ¦Â-CoVs; is a single , continuous domain of; lineage)

We introduced silent mutations in the codon optimized coding sequence for SARS-CoV to facilitate replacing the SARS RBD with the RBD from other lineage B viruses (figure 1b).
0.815: (We; introduced silent mutations in; the codon)
0.761: (We; introduced; silent mutations)
0.736: (silent mutations; be introduced in; the codon)
0.498: (the SARS RBD; be replacing with; the RBD)
0.497: (We; introduced silent mutations; the codon)
0.408: (the SARS RBD; be replacing from; other lineage B viruses)

All lineage B sequences were downloaded from online repositories and parsed to 29 unique RBD sequences, representing all published variations of the lineage B RBD (supp.
0.9: (All lineage B sequences; parsed to; 29 unique RBD sequences)
0.832: (All lineage B sequences; were downloaded from; online repositories)
0.826: (All lineage B sequences; were; downloaded)
0.662: (All lineage B sequences; parsed representing; all published variations of the lineage B RBD)

fig 1a, b).
No extractions found.

The panel of 29 RBDs phylogenetically cluster into 3 clades, as previously described5, but these RBD clades were not apparent in phylogenetic analysis of other viral sequences, such as the RNA-dependent RNA polymerase (supp.
0.837: (these RBD clades; were not apparent in; phylogenetic analysis of other viral sequences)
0.794: (The panel of 29 RBDs; phylogenetically cluster into; 3 clades)
0.769: (these RBD clades; were; not apparent)
0.586: (these RBD clades; were not apparent as; the RNA-dependent RNA polymerase)

fig 1c).
No extractions found.

All 29 RBDs were codon optimized, synthesized and cloned in place of the SARS RBD, effectively generating chimeric spike expression constructs.
No extractions found.

We then generated VSV-luciferase reporter particles pseudotyped with the chimeric spikes (figure 1c).
No extractions found.

We chose VSV over lentiviruses as our pseudotype platform because a lentiviral pseudotypes have failed to accurately reflect viral entry with novel bat coronavirus spike protein7.
0.832: (We; chose VSV over lentiviruses as; our pseudotype platform)[enabler=because a lentiviral pseudotypes have failed to accurately reflect viral entry with novel bat coronavirus spike protein7]
0.758: (We; chose; VSV)[enabler=because a lentiviral pseudotypes have failed to accurately reflect viral entry with novel bat coronavirus spike protein7]
0.696: (a lentiviral pseudotypes; have failed to accurately reflect; viral entry)
0.568: (VSV; be chose as; our pseudotype platform)[enabler=because a lentiviral pseudotypes have failed to accurately reflect viral entry with novel bat coronavirus spike protein7]

All constructs exhibited similar levels of expression in producer cells and incorporation into VSV pseudotypes, except the chimera with BM48-31 which displayed somewhat reduced expression compared to WT SARS spike (figure 1d).
0.877: (All constructs; exhibited; similar levels of expression)
0.8: (All constructs; exhibited similar levels of expression in producer cells and incorporation except; the chimera)
0.767: (All constructs; exhibited similar levels of expression in producer cells and incorporation into; VSV pseudotypes)
0.724: (similar levels of expression; be exhibited into; VSV pseudotypes)
0.674: (similar levels of expression; be exhibited except; the chimera)

We then infected BHK cells expressing the receptor for SARS-CoV or empty vector (figure 1e) and observed only clade 1, which includes SARS-CoV, WIV1 and SHC014, could enter cells transfected with human ACE2 (figure 1e).
0.696: (SARS-CoV , WIV1 and SHC014; could enter; cells transfected with human ACE2 ( figure 1e ))
0.614: (We; then infected; BHK cells)

After binding the host receptor, host-cell protease cleaves spike, releasing the fusion peptide and allowing for host cell entry 20.
No extractions found.

Previous studies have shown that absence of the host protease or incompatibility between the host protease and viral spike can block viral entry 21-24.
0.773: (that absence of the host protease; can block; viral entry 21-24)

To circumvent host-cell protease incompatibility or absence, we treated our lineage B pseudotype panel and infected a wide variety of cell types from different host species (figure 2, supp.
0.736: (a wide variety of cell types; be infected from; different host species)
0.611: (we; treated; our lineage B pseudotype panel)

fig.
No extractions found.

2).
No extractions found.

In the absence of exogenous protease, only clade 1 infected cells from African green monkey kidney, human gastrointestinal tract, human liver, and porcine kidney, in agreement with previous studies (figure 2; supp.
0.659: (1 infected cells; be only clade human liver from; African green monkey kidney)
0.659: (1 infected cells; be only clade porcine kidney from; African green monkey kidney)
0.644: (human gastrointestinal tract , human liver , and porcine kidney; be only clade 1 infected cells in; the absence of exogenous protease)
0.577: (human gastrointestinal tract , human liver , and porcine kidney; be only clade 1 infected cells from; African green monkey kidney)
0.487: (1 infected cells; be only clade human gastrointestinal tract , human liver , and porcine kidney , in agreement with previous studies ( figure 2 ; supp from; African green monkey kidney)
0.386: (1 infected cells; be only clade human liver in; the absence of exogenous protease)
0.386: (1 infected cells; be only clade porcine kidney in; the absence of exogenous protease)
0.381: (1 infected cells; be only clade human gastrointestinal tract , human liver , and porcine kidney , in agreement with previous studies ( figure 2 ; supp in; the absence of exogenous protease)

fig.
No extractions found.

2a, b).
No extractions found.

Surprisingly, exogenous protease enhanced entry of a subset of clade 2 spike chimeras in nonhuman primate, bat and human cells (figure 2).
No extractions found.

Importantly, VSV-g pseudotyped particles were able to produce luciferase signal in all cell lines tested in this study (supp.
0.796: (luciferase signal; to be produce in; all cell lines tested in this study ( supp)
0.778: (particles; to produce; luciferase signal)
0.655: (all cell lines; be tested in; this study)
0.497: (particles; were; able)

fig.
No extractions found.

2c).
No extractions found.

We next tested human variants of known ¦Â-CoV receptors for their ability to mediate cell entry of clade 2 and 3 spike chimeras.
0.795: (We; tested; human variants of known ¦Â-CoV receptors)
0.79: (We; tested human variants of known ¦Â-CoV receptors for; their ability to mediate cell entry of clade 2 and 3 spike chimeras)

We also tested human aminopeptidase N (APN), a receptor for alphacoronaviruses, which have been shown to utilize either human ACE2 or human APN for cell entry (figure 3a).
0.685: (We; also tested; human aminopeptidase N)
0.53: (APN); be a receptor for; alphacoronaviruses which have been shown to utilize either human ACE2 or human APN for cell entry ( figure 3a ))

Protease treatment only enhanced entry of clade 1 RBDs on cells expressing human ACE2, but not human DPP4 or APN.
No extractions found.

No entry was observed with clade 2 or 3 spikes, regardless of receptor or protease addition.
0.828: (No entry; was observed regardless of receptor protease addition with; clade 2 or 3 spikes)

Human dipeptidyl peptidase IV (DPP4), the receptor for the lineage C ¦Â-CoVs, MERS-CoV, only mediated entry of MERS-CoV (figure 2b, middle panels).
0.361: (DPP4); be the receptor for; the lineage C ¦Â-CoVs)
0.239: (DPP4); be mediated entry of; MERS-CoV)

Importantly, in the absence of receptor, no entry was observed for any of the pseudotypes, suggesting that protease-mediated entry is receptor-dependent (figure 2b, right panels).
0.85: (no entry; Importantly was observed in; the absence of receptor)
0.598: (protease-mediated entry; is; receptor-dependent)

While our study was ongoing, a novel lineage B virus tentatively named 2019nCoV was identified as the cause of a pneumonia outbreak in Hubei, China.
0.96: (2019nCoV; was identified as; the cause of a pneumonia outbreak)
0.624: (our study; was; ongoing)
0.533: (2019nCoV; be the cause of; a pneumonia outbreak)

Once the sequence was publicly available, we synthesized, cloned and tested the RBD from 2019nCoV in our assay with human variants of known coronavirus receptors.
0.93: (available; tested the RBD with; human variants of known coronavirus receptors)
0.926: (available; tested the RBD from; 2019nCoV)
0.875: (available; tested the RBD in; our assay)
0.849: (available; tested; the RBD)
0.75: (the RBD; be tested with; human variants of known coronavirus receptors)
0.705: (the sequence; Once was publicly; available)
0.685: (the RBD; be tested from; 2019nCoV)
0.625: (the RBD; be tested in; our assay)

The chimeric SARS-2019-nCoV spike protein expressed and was incorporated into particles similarly to other clade 1 chimeric spikes (figure 3c).
No extractions found.

The 2019-nCoV RBD was capable of entering cells expressing human ACE2, but not any of the other receptors tested (figure 3d; s3).
0.699: (The 2019-nCoV RBD; was capable of; entering cells expressing human ACE2)
0.542: (The 2019-nCoV RBD; was; capable of entering cells)

Consensus sequences of the three lineage B clades showed several key differences between these groups.
0.828: (Consensus sequences of the three lineage B clades; showed; several key differences)

Only clade 1 RBDs contain all 14 residues that have been shown through crystallography, to interact with human ACE2 (figure 4a; s4).
0.638: (1 RBDs; contain; all 14 residues that have been shown through crystallography to interact with human ACE2 ( figure 4a)

The majority of these residues are absent from clades 2 and 3, which contain additional deletions in surface exposed loops that cluster at the interface with ACE2 (figure 4 a, b).
0.882: (The majority of these residues; are absent from; clades 2 and 3 , which contain additional deletions in surface exposed loops that cluster at the interface with ACE2 ( figure 4 a , b ))
0.696: (surface; exposed; loops)
0.492: (absent; be The majority of; these residues)

We generated a series of clade consensus RBD variants to determine the minimum number of mutations needed to impart ACE2 function on clade 2 and 3 RBDs (figure 4c).
0.789: (a series of clade consensus RBD; variants to determine; the minimum number of mutations)

Introducing the two loop deletions from clade 1 in clade 2 results in a reduced spike expression, impaired pseudotype incorporation and loss of cell entry (figure 4c, d).
No extractions found.

Restoring these loops in clade 2 and 3 from the loops found in clade 1 did not enhance entry with ACE2 (figure 4c; 2¡ú1 and 3¡ú1 version 1).
0.816: (these loops; be Restoring in; clade 2 and 3)
0.752: (these loops; be Restoring from; the loops)

Introducing all 14 ACE2 contact points in clade 2 or 3 also failed to restore ACE2 entry (figure 4c; 2¡ú1 and 3¡ú1 version 2).
0.752: (all 14 ACE2 contact points; be Introducing in; clade 2 or 3)

Only replacing all 14 contact points and the surrounding amino acids (also known as the receptor binding motif, RBM) lead to increased ACE2 entry with clade 2 and 3 RBDs (figure 4c; 2¡ú1 version 3 = clade 2 residues 322-400 + clade 1 residues 400-501; 3¡ú1 version 3 = clade 3 residues 322-385 + clade 1 residues 386-501).
0.564: (400-501; be residues by; + clade)
0.545: (1; residues; 400-501)

Taken together, these results show that the entire RBM from clade 1 is needed for ACE2 entry.
0.888: (the entire RBM; is needed for; ACE2 entry)[attrib=these results show]

We next synthesized full-length clade 2 and 3 spikes to compare to our RBD chimeras.
No extractions found.

We selected the clade 2 spike, As6526, because it consistently gave strong entry signal in human cells following protease-treatment (figure 2b) as well as BM48-31, the only clade 3 spike in our panel.
0.736: (strong entry signal; be consistently gave following; protease-treatment)
0.736: (strong entry signal; be consistently gave in; human cells)
0.722: (it; consistently gave strong entry signal in; human cells)
0.684: (We; selected; the clade 2 spike)[enabler=because it consistently gave strong entry signal in human cells following protease-treatment ( figure 2b ) as well as BM48-31 , the only clade 3 spike in our panel]
0.669: (it; consistently gave strong entry signal following; protease-treatment)
0.653: (it; consistently gave; strong entry signal)

As we did for SARS-CoV spike, clade 2 and 3 spikes were codon optimized, FLAG-tagged and silent mutations were introduced to facilitate replacing their RBD with the consensus RBD from clade 1 (figure 5a).
0.771: (their RBD; be replacing with; the consensus RBD)
0.718: (we; did for; SARS-CoV spike)
0.696: (their RBD; be replacing from; clade 1)

All chimeric constructs expressed similarly, with the exception for the SARS-BM48-31 RBD chimera, which exhibited reduced expression and incorporation (figure 5b).
0.89: (All chimeric constructs; expressed similarly with; the exception)

Protease treatment enhanced entry of both the As6526 clade 2 RBD chimera and full-length spike entry into Huh cells (figure 5c).
No extractions found.

Protease treatment had no effect on either the BM48-31 clade 3 chimera or full-length spike (figure 5c).
0.792: (Protease treatment; had; no effect)

Taken together, these findings show that SARSlineage B RBD chimeras reflect the entry phenotype of full-length lineage B spikes.
0.589: (SARSlineage B RBD chimeras; reflect; the entry phenotype of full-length lineage B spikes)[attrib=these findings show]

Finally, we tested if receptor-binding and protease processing are coupled.
No extractions found.

We replaced the RBD of full-length clade 2 and 3 spike with the consensus RBD from clade 1 and tested pseudotypes on cells expressing the clade 1 receptor.
0.834: (We; replaced; the RBD of full-length clade 2 and 3 spike with the consensus RBD from clade 1 and tested pseudotypes)

The clade 1 consensus RBD efficiently facilitated entry of both As6526 and BM48-31 spike only following protease treatment.
0.876: (The clade 1 consensus RBD; efficiently facilitated; entry of both As6526 and BM48-31 spike only following protease treatment)

These findings show that even though BHK-hACE2 cells support full-length clade 1 spike entry, just having the RBD from a clade 1 virus is insufficient to mediate entry.
0.408: (the RBD; be just having from; a clade 1 virus)
0.269: (BHK-hACE2 cells; that even support; full-length clade)[attrib=These findings show]

As seen in our previous experiments, protease treatment did not enhance pseudotype entry in the absence of host receptor (figure 5).
0.798: (protease treatment; did not enhance; pseudotype entry)[enabler=As seen in our previous experiments]

The receptor binding domain (RBD) of lineage B ¦Â-CoVs is a single, continuous domain that contains all structural information necessary to interact with the host receptor (figure 1a, b).
0.599: (all structural information necessary; be contains by; lineage B ¦Â-CoVs is a single , continuous domain)
0.55: (B ¦Â-CoVs; is a single , continuous domain of; lineage)

We introduced silent mutations in the codon optimized coding sequence for SARS-CoV to facilitate replacing the SARS RBD with the RBD from other lineage B viruses (figure 1b).
0.815: (We; introduced silent mutations in; the codon)
0.761: (We; introduced; silent mutations)
0.736: (silent mutations; be introduced in; the codon)
0.498: (the SARS RBD; be replacing with; the RBD)
0.497: (We; introduced silent mutations; the codon)
0.408: (the SARS RBD; be replacing from; other lineage B viruses)

All lineage B sequences were downloaded from online repositories and parsed to 29 unique RBD sequences, representing all published variations of the lineage B RBD (supp.
0.9: (All lineage B sequences; parsed to; 29 unique RBD sequences)
0.832: (All lineage B sequences; were downloaded from; online repositories)
0.826: (All lineage B sequences; were; downloaded)
0.662: (All lineage B sequences; parsed representing; all published variations of the lineage B RBD)

fig 1a, b).
No extractions found.

The panel of 29 RBDs phylogenetically cluster into 3 clades, as previously described5, but these RBD clades were not apparent in phylogenetic analysis of other viral sequences, such as the RNA-dependent RNA polymerase (supp.
0.837: (these RBD clades; were not apparent in; phylogenetic analysis of other viral sequences)
0.794: (The panel of 29 RBDs; phylogenetically cluster into; 3 clades)
0.769: (these RBD clades; were; not apparent)
0.586: (these RBD clades; were not apparent as; the RNA-dependent RNA polymerase)

fig 1c).
No extractions found.

All 29 RBDs were codon optimized, synthesized and cloned in place of the SARS RBD, effectively generating chimeric spike expression constructs.
No extractions found.

We then generated VSV-luciferase reporter particles pseudotyped with the chimeric spikes (figure 1c).
No extractions found.

We chose VSV over lentiviruses as our pseudotype platform because a lentiviral pseudotypes have failed to accurately reflect viral entry with novel bat coronavirus spike protein7.
0.832: (We; chose VSV over lentiviruses as; our pseudotype platform)[enabler=because a lentiviral pseudotypes have failed to accurately reflect viral entry with novel bat coronavirus spike protein7]
0.758: (We; chose; VSV)[enabler=because a lentiviral pseudotypes have failed to accurately reflect viral entry with novel bat coronavirus spike protein7]
0.696: (a lentiviral pseudotypes; have failed to accurately reflect; viral entry)
0.568: (VSV; be chose as; our pseudotype platform)[enabler=because a lentiviral pseudotypes have failed to accurately reflect viral entry with novel bat coronavirus spike protein7]

All constructs exhibited similar levels of expression in producer cells and incorporation into VSV pseudotypes, except the chimera with BM48-31 which displayed somewhat reduced expression compared to WT SARS spike (figure 1d).
0.877: (All constructs; exhibited; similar levels of expression)
0.8: (All constructs; exhibited similar levels of expression in producer cells and incorporation except; the chimera)
0.767: (All constructs; exhibited similar levels of expression in producer cells and incorporation into; VSV pseudotypes)
0.724: (similar levels of expression; be exhibited into; VSV pseudotypes)
0.674: (similar levels of expression; be exhibited except; the chimera)

We then infected BHK cells expressing the receptor for SARS-CoV or empty vector (figure 1e) and observed only clade 1, which includes SARS-CoV, WIV1 and SHC014, could enter cells transfected with human ACE2 (figure 1e).
0.696: (SARS-CoV , WIV1 and SHC014; could enter; cells transfected with human ACE2 ( figure 1e ))
0.614: (We; then infected; BHK cells)

After binding the host receptor, host-cell protease cleaves spike, releasing the fusion peptide and allowing for host cell entry 20.
No extractions found.

Previous studies have shown that absence of the host protease or incompatibility between the host protease and viral spike can block viral entry 21-24.
0.773: (that absence of the host protease; can block; viral entry 21-24)

To circumvent host-cell protease incompatibility or absence, we treated our lineage B pseudotype panel and infected a wide variety of cell types from different host species (figure 2, supp.
0.736: (a wide variety of cell types; be infected from; different host species)
0.611: (we; treated; our lineage B pseudotype panel)

fig.
No extractions found.

2).
No extractions found.

In the absence of exogenous protease, only clade 1 infected cells from African green monkey kidney, human gastrointestinal tract, human liver, and porcine kidney, in agreement with previous studies (figure 2; supp.
0.659: (1 infected cells; be only clade human liver from; African green monkey kidney)
0.659: (1 infected cells; be only clade porcine kidney from; African green monkey kidney)
0.644: (human gastrointestinal tract , human liver , and porcine kidney; be only clade 1 infected cells in; the absence of exogenous protease)
0.577: (human gastrointestinal tract , human liver , and porcine kidney; be only clade 1 infected cells from; African green monkey kidney)
0.487: (1 infected cells; be only clade human gastrointestinal tract , human liver , and porcine kidney , in agreement with previous studies ( figure 2 ; supp from; African green monkey kidney)
0.386: (1 infected cells; be only clade human liver in; the absence of exogenous protease)
0.386: (1 infected cells; be only clade porcine kidney in; the absence of exogenous protease)
0.381: (1 infected cells; be only clade human gastrointestinal tract , human liver , and porcine kidney , in agreement with previous studies ( figure 2 ; supp in; the absence of exogenous protease)

fig.
No extractions found.

2a, b).
No extractions found.

Surprisingly, exogenous protease enhanced entry of a subset of clade 2 spike chimeras in nonhuman primate, bat and human cells (figure 2).
No extractions found.

Importantly, VSV-g pseudotyped particles were able to produce luciferase signal in all cell lines tested in this study (supp.
0.796: (luciferase signal; to be produce in; all cell lines tested in this study ( supp)
0.778: (particles; to produce; luciferase signal)
0.655: (all cell lines; be tested in; this study)
0.497: (particles; were; able)

fig.
No extractions found.

2c).
No extractions found.

We next tested human variants of known ¦Â-CoV receptors for their ability to mediate cell entry of clade 2 and 3 spike chimeras.
0.795: (We; tested; human variants of known ¦Â-CoV receptors)
0.79: (We; tested human variants of known ¦Â-CoV receptors for; their ability to mediate cell entry of clade 2 and 3 spike chimeras)

We also tested human aminopeptidase N (APN), a receptor for alphacoronaviruses, which have been shown to utilize either human ACE2 or human APN for cell entry (figure 3a).
0.685: (We; also tested; human aminopeptidase N)
0.53: (APN); be a receptor for; alphacoronaviruses which have been shown to utilize either human ACE2 or human APN for cell entry ( figure 3a ))

Protease treatment only enhanced entry of clade 1 RBDs on cells expressing human ACE2, but not human DPP4 or APN.
No extractions found.

No entry was observed with clade 2 or 3 spikes, regardless of receptor or protease addition.
0.828: (No entry; was observed regardless of receptor protease addition with; clade 2 or 3 spikes)

Human dipeptidyl peptidase IV (DPP4), the receptor for the lineage C ¦Â-CoVs, MERS-CoV, only mediated entry of MERS-CoV (figure 2b, middle panels).
0.361: (DPP4); be the receptor for; the lineage C ¦Â-CoVs)
0.239: (DPP4); be mediated entry of; MERS-CoV)

Importantly, in the absence of receptor, no entry was observed for any of the pseudotypes, suggesting that protease-mediated entry is receptor-dependent (figure 2b, right panels).
0.85: (no entry; Importantly was observed in; the absence of receptor)
0.598: (protease-mediated entry; is; receptor-dependent)

While our study was ongoing, a novel lineage B virus tentatively named 2019nCoV was identified as the cause of a pneumonia outbreak in Hubei, China.
0.96: (2019nCoV; was identified as; the cause of a pneumonia outbreak)
0.624: (our study; was; ongoing)
0.533: (2019nCoV; be the cause of; a pneumonia outbreak)

Once the sequence was publicly available, we synthesized, cloned and tested the RBD from 2019nCoV in our assay with human variants of known coronavirus receptors.
0.93: (available; tested the RBD with; human variants of known coronavirus receptors)
0.926: (available; tested the RBD from; 2019nCoV)
0.875: (available; tested the RBD in; our assay)
0.849: (available; tested; the RBD)
0.75: (the RBD; be tested with; human variants of known coronavirus receptors)
0.705: (the sequence; Once was publicly; available)
0.685: (the RBD; be tested from; 2019nCoV)
0.625: (the RBD; be tested in; our assay)

The chimeric SARS-2019-nCoV spike protein expressed and was incorporated into particles similarly to other clade 1 chimeric spikes (figure 3c).
No extractions found.

The 2019-nCoV RBD was capable of entering cells expressing human ACE2, but not any of the other receptors tested (figure 3d; s3).
0.699: (The 2019-nCoV RBD; was capable of; entering cells expressing human ACE2)
0.542: (The 2019-nCoV RBD; was; capable of entering cells)

Consensus sequences of the three lineage B clades showed several key differences between these groups.
0.828: (Consensus sequences of the three lineage B clades; showed; several key differences)

Only clade 1 RBDs contain all 14 residues that have been shown through crystallography, to interact with human ACE2 (figure 4a; s4).
0.638: (1 RBDs; contain; all 14 residues that have been shown through crystallography to interact with human ACE2 ( figure 4a)

The majority of these residues are absent from clades 2 and 3, which contain additional deletions in surface exposed loops that cluster at the interface with ACE2 (figure 4 a, b).
0.882: (The majority of these residues; are absent from; clades 2 and 3 , which contain additional deletions in surface exposed loops that cluster at the interface with ACE2 ( figure 4 a , b ))
0.696: (surface; exposed; loops)
0.492: (absent; be The majority of; these residues)

We generated a series of clade consensus RBD variants to determine the minimum number of mutations needed to impart ACE2 function on clade 2 and 3 RBDs (figure 4c).
0.789: (a series of clade consensus RBD; variants to determine; the minimum number of mutations)

Introducing the two loop deletions from clade 1 in clade 2 results in a reduced spike expression, impaired pseudotype incorporation and loss of cell entry (figure 4c, d).
No extractions found.

Restoring these loops in clade 2 and 3 from the loops found in clade 1 did not enhance entry with ACE2 (figure 4c; 2¡ú1 and 3¡ú1 version 1).
0.816: (these loops; be Restoring in; clade 2 and 3)
0.752: (these loops; be Restoring from; the loops)

Introducing all 14 ACE2 contact points in clade 2 or 3 also failed to restore ACE2 entry (figure 4c; 2¡ú1 and 3¡ú1 version 2).
0.752: (all 14 ACE2 contact points; be Introducing in; clade 2 or 3)

Only replacing all 14 contact points and the surrounding amino acids (also known as the receptor binding motif, RBM) lead to increased ACE2 entry with clade 2 and 3 RBDs (figure 4c; 2¡ú1 version 3 = clade 2 residues 322-400 + clade 1 residues 400-501; 3¡ú1 version 3 = clade 3 residues 322-385 + clade 1 residues 386-501).
0.564: (400-501; be residues by; + clade)
0.545: (1; residues; 400-501)

Taken together, these results show that the entire RBM from clade 1 is needed for ACE2 entry.
0.888: (the entire RBM; is needed for; ACE2 entry)[attrib=these results show]

We next synthesized full-length clade 2 and 3 spikes to compare to our RBD chimeras.
No extractions found.

We selected the clade 2 spike, As6526, because it consistently gave strong entry signal in human cells following protease-treatment (figure 2b) as well as BM48-31, the only clade 3 spike in our panel.
0.736: (strong entry signal; be consistently gave following; protease-treatment)
0.736: (strong entry signal; be consistently gave in; human cells)
0.722: (it; consistently gave strong entry signal in; human cells)
0.684: (We; selected; the clade 2 spike)[enabler=because it consistently gave strong entry signal in human cells following protease-treatment ( figure 2b ) as well as BM48-31 , the only clade 3 spike in our panel]
0.669: (it; consistently gave strong entry signal following; protease-treatment)
0.653: (it; consistently gave; strong entry signal)

As we did for SARS-CoV spike, clade 2 and 3 spikes were codon optimized, FLAG-tagged and silent mutations were introduced to facilitate replacing their RBD with the consensus RBD from clade 1 (figure 5a).
0.771: (their RBD; be replacing with; the consensus RBD)
0.718: (we; did for; SARS-CoV spike)
0.696: (their RBD; be replacing from; clade 1)

All chimeric constructs expressed similarly, with the exception for the SARS-BM48-31 RBD chimera, which exhibited reduced expression and incorporation (figure 5b).
0.89: (All chimeric constructs; expressed similarly with; the exception)

Protease treatment enhanced entry of both the As6526 clade 2 RBD chimera and full-length spike entry into Huh cells (figure 5c).
No extractions found.

Protease treatment had no effect on either the BM48-31 clade 3 chimera or full-length spike (figure 5c).
0.792: (Protease treatment; had; no effect)

Taken together, these findings show that SARSlineage B RBD chimeras reflect the entry phenotype of full-length lineage B spikes.
0.589: (SARSlineage B RBD chimeras; reflect; the entry phenotype of full-length lineage B spikes)[attrib=these findings show]

Finally, we tested if receptor-binding and protease processing are coupled.
No extractions found.

We replaced the RBD of full-length clade 2 and 3 spike with the consensus RBD from clade 1 and tested pseudotypes on cells expressing the clade 1 receptor.
0.834: (We; replaced; the RBD of full-length clade 2 and 3 spike with the consensus RBD from clade 1 and tested pseudotypes)

The clade 1 consensus RBD efficiently facilitated entry of both As6526 and BM48-31 spike only following protease treatment.
0.876: (The clade 1 consensus RBD; efficiently facilitated; entry of both As6526 and BM48-31 spike only following protease treatment)

These findings show that even though BHK-hACE2 cells support full-length clade 1 spike entry, just having the RBD from a clade 1 virus is insufficient to mediate entry.
0.408: (the RBD; be just having from; a clade 1 virus)
0.269: (BHK-hACE2 cells; that even support; full-length clade)[attrib=These findings show]

As seen in our previous experiments, protease treatment did not enhance pseudotype entry in the absence of host receptor (figure 5).
0.798: (protease treatment; did not enhance; pseudotype entry)[enabler=As seen in our previous experiments]

Despite significant advances in next generation sequencing technologies, which have facilitated the discovery of thousands of novel animal-derived viruses, tools for downstream functional assessment of these novel sequences are lacking.
0.368: (tools; are lacking despite; significant advances)

To gain traction on this ever-growing problem, we took a reductionist approach to coronavirus entry and developed a scalable, BSL2-compatible method for testing only the minimal region of the virus essential for interacting with the host receptor (figure 1, figure s1a).
0.75: (we; developed; a scalable , BSL2-compatible method)
0.75: (we; took; a reductionist approach)
0.633: (the minimal region of the virus; testing essential for; interacting)
0.399: (essential; be only the minimal region of; the virus)
0.276: (minimal; be only region of; the virus)

Because most of these viruses have never been isolated, we resorted to synthetic biology and molecular engineering to reduce the burden of gene synthesis to just a small fragment.
0.859: (we; resorted to; synthetic biology and molecular engineering)[enabler=Because most of these viruses have never been isolated]
0.738: (we; resorted to reduce the burden of gene synthesis to; a small fragment)[enabler=Because most of these viruses have never been isolated]
0.708: (the burden of gene synthesis; to reduce to be; a small fragment)
0.692: (we; resorted to reduce; the burden of gene synthesis)[enabler=Because most of these viruses have never been isolated]

Thus, the cost and synthesis production time for testing several spikes for entry in our system is dramatically reduced (figure s1d).
0.707: (several spikes; be testing for; entry)
0.652: (the cost and synthesis production time; Thus is dramatically; reduced)
0.542: (several spikes; be testing in; our system)

In theory, this approach to functional viromics should be applicable to a wide variety of virus-host proteins and interactions.
0.837: (this approach; should be applicable to; a wide variety of virus-host proteins)
0.778: (this approach; should be; applicable)
0.572: (this approach; should be applicable in; theory)
0.351: (applicable; be this approach to; functional viromics)

Coronavirus entry is a multi-step process involving multiple, distinct domains in spike that mediate virus attachment to the cell surface, receptor engagement, protease processing and membrane fusion8.
0.802: (Coronavirus entry; is; a multi-step process involving multiple , distinct domains in spike that mediate virus attachment to the cell surface , receptor engagement , protease processing and membrane fusion8)
0.707: (multiple , distinct domains; be involving in; spike)
0.684: (a multi-step process; involving multiple , distinct domains in; spike)

While the RBD:receptor interaction is most studied in this process, recent studies have highlighted the major role host protease processing plays as a species barrier22,25-27.
0.823: (recent studies; have highlighted the major role host protease processing plays as; a species barrier22,25-27)[enabler=While the RBD :receptor interaction is most studied in this process]
0.785: (recent studies; have highlighted; the major role host protease processing plays)[enabler=While the RBD :receptor interaction is most studied in this process]
0.739: (the RBD :receptor interaction; is studied in; this process)

Lineage C coronaviruses include MERS-CoV as well as distantly related viruses such as HKU4, HKU5 and PDF-2180 28,29.
0.794: (Lineage C coronaviruses; include; MERS-CoV as well as distantly related viruses)

Studies have shown that HKU4 can bind human DPP4 but requires addition of exogenous trypsin to facilitate cell entry and that HKU5 and PDF-2180 spikes can enter human cells through an unidentified receptor with protease treatment22,26.
0.739: (human cells; can be enter through; an unidentified receptor)
0.71: (HKU5 and PDF-2180 spikes; can enter human cells through; an unidentified receptor)
0.624: (HKU5 and PDF-2180 spikes; can enter; human cells)
0.36: (addition of exogenous trypsin; to facilitate that HKU5 and PDF-2180 spikes can enter human cells through an unidentified receptor with protease treatment22,26; cell entry)

Analogous to these earlier studies of lineage C CoVs, we observed protease-enhanced entry of lineage B CoVs (figure 2, 3, 5).
0.74: (we; observed; protease-enhanced entry of lineage B CoVs)

While it has been shown that host proteases cleave spike, allowing for downstream membrane fusion, other evidence suggests that protease may act on the receptor as well to activate it30.
0.631: (protease; to activate; it30)
0.628: (protease; may act as well on; the receptor)
0.509: (protease; may act as well to activate; it30)
0.365: (it; has been shown allowing for; downstream membrane fusion)

Addition of protease during the course of SARS-CoV infection facilitated entry in cells with low-expression of ACE2 that is normally insufficient to support virus entry30.
0.903: (Addition of protease; facilitated entry in cells with; low-expression of ACE2)
0.837: (Addition of protease; facilitated; entry)
0.785: (entry; be facilitated with; low-expression of ACE2)

Indeed, we saw evidence of residual trypsin activity on the cells after infection in our studies as the cell monolayer was loose compared to the untreated condition.
0.805: (evidence of residual trypsin activity; be Indeed saw after; infection)
0.766: (we; Indeed saw; evidence of residual trypsin activity)
0.702: (we; Indeed saw evidence of residual trypsin activity on the cells after; infection)

Similarly, Menachery et al. also observed cell rounding during their trypsin infections26.
0.859: (Menachery et al; also observed cell rounding during; their trypsin infections26)
0.82: (Menachery et al; also observed; cell rounding)
0.717: (cell rounding; be also observed during; their trypsin infections26)

Therefore, further studies are needed to assess where trypsin is enhancing entry of coronaviruses: at the level of spike, the receptor, or both.
0.667: (trypsin; is enhancing; entry of coronaviruses)

In the absence of exogenous protease, only clade 1 RBDs entered nonhuman primate, human and porcine cell lines (figure 2a, b, s2a, b).
0.595: (1 RBDs; entered; nonhuman primate , human and porcine cell lines)

These findings are in strong agreement with previous studies that have either isolated virus (WIV1) or rescued recombinant chimeric viruses (SHC014, Rs4231, Rs7237)5,7,31.
0.85: (These findings; are in; strong agreement)
0.444: (Rs4231; be SHC014 rs7237)5; ,7,31)

However, with trypsin, a subset of genetically-similar clade 2 RBDs gained entry in these cells, suggesting their barrier is at the level of protease processing (figure 2a, b).
0.899: (a subset of genetically-similar clade suggesting their barrier; However is at; the level of protease processing)
0.758: (a subset of genetically-similar clade suggesting their barrier; However is with; trypsin)

The other spike from clade 2 and 3 did not enter the cells we tested, regardless of protease addition, suggesting an absent or incompatible receptor.
0.583: (The other spike; did not enter regardless of protease addition; the cells we tested)
0.416: (The other spike; did not enter the cells we tested regardless of protease addition suggesting; an absent or incompatible receptor)

Surprisingly, the protease-dependent entry phenotype was consistent in the reverse spike chimeras in which we replaced the RBD in clade 2 or 3 spike with a clade 1 RBD (figure 5d), suggesting that either the protease site between S1/S2 is not compatible with the chimeric spike backbone or the protease is not expressed in these cells (figure s5).
0.885: (we; replaced the RBD in; clade 2 or 3 spike)
0.84: (the protease-dependent entry phenotype; Surprisingly was consistent in; the reverse spike chimeras in which we replaced the RBD in clade 2 or 3 spike with a clade 1 RBD ( figure 5d ) , suggesting that either the protease site between S1/S2 is not compatible with the chimeric spike backbone or the protease is not expressed in these cells ( figure s5 ))
0.824: (the protease site; is not compatible with; the chimeric spike backbone or the protease)
0.788: (we; replaced; the RBD)
0.778: (the protease-dependent entry phenotype; Surprisingly was; consistent)
0.767: (the protease site; is; not compatible)
0.685: (the RBD; be replaced in; clade 2 or 3 spike)
0.372: (not compatible; be the protease site between; S1/S2)

Because clade 1 spikes enter cells expressing human ACE2 without addition of protease but clade2-clade1 chimeras require protease, our data suggests the spike protease cleavage site is adapted to the protease environment of the receptor-bound RBD (figure s5).
0.922: (the spike protease cleavage site; is adapted to; the protease environment of the receptor-bound RBD)
0.71: (clade 1 spikes; enter; cells expressing human ACE2)
0.652: (clade 1 spikes; enter cells expressing human ACE2 without; addition of protease)

None of the spike pseudotypes efficiently entered Rhinolophus cells, which has been observed in previous studies using these cells32,33 (figure 2c).
0.849: (None of the spike pseudotypes; efficiently entered; Rhinolophus cells which has been observed in previous studies)

Surprisingly, AJi cells were selectively permissive for only clade 2 entry following protease treatment, which suggests that clade 2 RBDs interact with a receptor that is distinct from clade 1 (figure 2c).
0.832: (following protease treatment; suggests that; clade 2 RBDs interact)
0.731: (AJi cells; Surprisingly were selectively permissive for; clade)
0.723: (AJi cells; Surprisingly were selectively; permissive)

Our results show that, despite all being classified as the same virus species, most lineage B ¦Â-CoVs do not use currently known coronavirus receptors (figure 1e, 3a, b).
0.717: (most lineage B ¦Â-CoVs; do not use; known coronavirus receptors)[attrib=Our results show]

Critically, we did not observe any pseudotype entry in the presence of protease and absence of receptor, suggesting that lineage B cell entry is still receptor-dependent following protease treatment (figure 3b).
0.832: (any pseudotype entry; Critically did not observe in; the presence of protease and absence of receptor)
0.773: (we; Critically did not observe any pseudotype entry in; the presence of protease and absence of receptor)
0.745: (lineage B cell entry; is still receptor-dependent following; protease treatment)
0.709: (we; Critically did not observe; any pseudotype entry)
0.654: (lineage B cell entry; is still; receptor-dependent)

While our study was ongoing, a novel lineage B ¦Â-CoV was identified as the etiological agent behind an outbreak of pneumonia in Wuhan, Hubei, China (2019-nCoV).
0.921: (a novel lineage B ¦Â-CoV; was identified as; the etiological agent)[enabler=While our study was ongoing]
0.624: (our study; was; ongoing)
0.345: (Hubei; be pneumonia in; Wuhan)

The RBD for 2019-nCoV has residues and motifs found in all 3 clades but forms a distinct clade, so we tested it for receptor usage and observed entry only with human ACE2 but not other known coronavirus receptors (figure 3d).
0.87: (residues and motifs; found in; all 3 clades)[enabler=so we tested it for receptor usage and observed entry only with human ACE2 but not other known coronavirus receptors ( figure 3d )]
0.722: (we; tested it for; receptor usage and observed entry)
0.634: (it; be tested for; receptor usage and observed entry)
0.585: (we; tested; it)

Interestingly, within the backbone of SARS-CoV spike, cell entry of 2019-nCoV was similar to the other clade 1 spikes tested, including SARS-CoV.
0.775: (cell entry of 2019-nCoV; Interestingly was similar to; the other clade 1 spikes tested)
0.768: (cell entry of 2019-nCoV; Interestingly was; similar)
0.696: (cell entry of 2019-nCoV; Interestingly was similar within; the backbone of SARS-CoV spike)

These finding suggests 2019-nCoV is capable of using human ACE2 as efficiently as SARS-CoV, which may help explain the human-to-human transmissibility of this virus.
0.707: (2019-nCoV; is; capable using human ACE2 as efficiently as SARS-CoV ,)

More studies are needed with the full spike sequence and, ideally, a viral isolate.
0.819: (More studies; are needed a viral isolate with; the full spike sequence)
0.752: (More studies; are needed; a viral isolate)

The receptor binding motif (RBM) is a small region in the C-terminal half of the RBD and contains all the residues that interface with the host receptor (figure 3a)15.
0.32: (small; is region in; the C-terminal half of the RBD)

The 14 contact points in the co-structure of the SARS-RBD bound to human ACE2 are largely absent from clade 2 and 3 RBDs, which also contain deletions compared to clade 1 RBMs (figure 4a, b, s4a).
0.637: (the co-structure of the SARS-RBD; bound to; human ACE2)

Simply mutating clade 2 and 3 to have the 14 contact points was insufficient to impart human ACE2 usage (figure 4c).
0.737: (the 14 contact points; was; insufficient)

This is likely because the noncontact residues in the RBM play a supportive and structural role for these contact points, and indeed, these non-contact residues are different between the clades (figure s4).
0.698: (the noncontact residues in the RBM play a supportive and structural role for these contact points , and indeed , these non-contact residues; are different between; the clades)
0.159: (different; be the noncontact residues indeed in; the RBM play)

In contrast to changing individual amino acids, our chimeric RBD constructs show that clade 2 and 3 RBD containing the clade 1 RBM are compatible with human ACE2.
0.55: (clade 2 and 3 RBD containing the clade 1 RBM; are compatible with; human ACE2)[attrib=individual show]

Coronaviruses frequently undergo recombination, gaining large swaths of genetic material at once 34,35.
0.767: (Coronaviruses; frequently undergo; recombination)
0.724: (large swaths of genetic material; be gaining at; 34,35)
0.682: (Coronaviruses; frequently undergo recombination gaining; large swaths of genetic material)
0.662: (Coronaviruses; frequently undergo recombination gaining large swaths of genetic material at; 34,35)

Taken together with our data, it is possible that recombination with a clade 1 virus will impart compatibility with human ACE2.
0.758: (recombination; will impart; compatibility)
0.685: (it; is; possible)
0.643: (possible; be Taken together with; our data)

Interestingly, the 2019-nCoV RBD forms a clade that is distinct from the other 3 clades (figure s1c).
No extractions found.

However, the 2019nCoV RBD contains most of the contact points with human ACE2 that are found in clade 1 as well as some amino acid variations that are unique to clade 2 and 3 (figure s4b).
0.802: (the 2019nCoV RBD; However contains; most of the contact points)

Taken together with our receptor assay results, it may be possible that 2019-nCoV arose from recombination between clade 1 and the other clades.
0.886: (2019-nCoV; arose from; recombination)
0.734: (it; may be; possible)
0.643: (possible; be Taken together with; our receptor assay results)

As we saw with the SARS-As6526 RBD (clade 2) spike chimera, full length As6526 spike entered cells following protease treatment, but BM48-31 (clade 3) spike did not (figure 2, 5c).
0.863: (( clade 2 ) spike chimera; entered cells following; protease treatment)
0.752: (( clade 2 ) spike chimera; entered; cells)
0.718: (we; saw with; the SARS-As6526 RBD)
0.555: (cells; be entered following; protease treatment)

These data show that the chimeric spikes generally reproduce the entry phenotypes of full-length spikes.
0.747: (the chimeric spikes; generally reproduce; the entry phenotypes of full-length spikes)[attrib=These data show]

Notably, the full length As6526 spike did not enter cells as efficiently as the SARS-As6526 chimera, suggesting that other human-cell adaptations are likely needed in As6526 spike.
0.829: (likely; be needed in; As6526 spike)
0.793: (the full length; Notably did not enter; cells)

The capacity to predict the zoonotic potential of newly detected viruses has been severely hindered by a lack of functional data for these novel animal virus sequences.
0.948: (The capacity to predict the zoonotic potential of newly detected viruses; has been severely hindered by; a lack of functional data)

Here, we have developed a rapid and cost-effective platform to functionally test large groups of related viruses for zoonotic potential.
0.711: (we; Here have developed; a rapid and cost-effective platform to functionally test large groups of related viruses for zoonotic potential)
0.708: (large groups of related viruses; to be functionally test for; zoonotic potential)
0.447: (large; be groups of; related viruses)

We found that several other lineage B coronaviruses are capable of entering human cells through an unknown receptor and that lineage B spike proteins can recombine to gain entry with a known host-receptor.
0.712: (lineage B spike proteins; can recombine to gain; entry)
0.554: (several other lineage B coronaviruses; can recombine to gain; entry)
0.551: (human cells; be entering through; an unknown receptor)

Taken together with the latest outbreak of 2019-nCoV in humans, these findings underscore the importance of continued surveillance of coronaviruses at the sequence and functional levels in order to better prepare for the next emerging virus.
0.864: (these findings; underscore; the importance of continued surveillance of coronaviruses)

We would like to thank Dr. Anthony Schountz for generously sharing primary artibeus cells, as well as Dr. Marcel Muller for providing the Rhinolophus cells used in this study.
0.741: (the Rhinolophus cells; be used in; this study)
0.705: (We; would like to thank; Dr. Anthony Schountz)
0.613: (We; to thank; Dr. Anthony Schountz)

We would also like to acknowledge Wu,F., Zhao,S., Yu,B., Chen,Y.-M., Wang,W., Hu,Y., Song,Z.-G., Tao,Z.-W., Tian,J.-H., Pei,Y.-Y., Yuan,M.L., Zhang,Y.-L., Dai,F.-H., Liu,Y., Wang,Q.-M., Zheng,J.-J., Xu,L., Holmes,E.C. and Zhang,Y.-Z, the Wuhan Institute of Virology, Chinese Academy of Medical Sciences & Peking Union Medical College, Chinese Center for Disease Control and Prevention, and Wuhan Jinyintan Hospitar for providing the genome sequence for 2019-nCoV and other essential outbreak information to the scientific community.
0.708: (We; would also like to acknowledge; Wu ,F. , Zhao ,S. , Yu,B. , Chen ,Y.-M. , Wang ,W. , Hu,Y. , Song ,Z.-G. , Tao ,Z.-W. , Tian,J.-H. , Pei,Y.-Y. , Yuan ,M.L. , Zhang ,Y.-L. , Dai ,F.-H. , Liu,Y. , Wang , Q.-M. , Zheng ,J.-J. , Xu,L. , Holmes ,E.C. and Zhang ,Y.-Z , the Wuhan Institute of Virology , Chinese Academy of Medical Sciences & Peking Union Medical College)
0.616: (We; to acknowledge; Wu ,F. , Zhao ,S. , Yu,B. , Chen ,Y.-M. , Wang ,W. , Hu,Y. , Song ,Z.-G. , Tao ,Z.-W. , Tian,J.-H. , Pei,Y.-Y. , Yuan ,M.L. , Zhang ,Y.-L. , Dai ,F.-H. , Liu,Y. , Wang , Q.-M. , Zheng ,J.-J. , Xu,L. , Holmes ,E.C. and Zhang ,Y.-Z , the Wuhan Institute of Virology , Chinese Academy of Medical Sciences & Peking Union Medical College)
0.608: (the genome sequence; be providing to; the scientific community)

This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases.
0.92: (This work; was supported by; the Intramural Research Program of the National Institute of Allergy)

The authors declare no competing interests.
0.767: (The authors; declare; no competing interests)

17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 a, Primate cells, b, human cells or c, bat cells were infected with VSV-particles pseudotyped with the lineage B chimeric spike panel.
0.948: (17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 a , Primate cells , b , human cells or c , bat cells; were infected with; VSV-particles pseudotyped with the lineage B chimeric spike panel)
0.705: (VSV-particles; be pseudotyped with; the lineage B chimeric spike panel)

Pseudotypes were either left untreated or incubated with trypsin before addition to the cells.
0.911: (Pseudotypes; were either left before; addition)
0.911: (Pseudotypes; were either left with; trypsin)

Luciferase was measured and normalized to particles produced without pseudotype.
0.94: (Luciferase; be normalized to; particles produced without pseudotype)
0.705: (particles; be produced without; pseudotype)

Shown are the data for 3 replicates.
No extractions found.

a, Schematic of known coronavirus RBDs and their receptors.
No extractions found.

b, Pseudotyped particles were either left untreated and treated with trypsin and subsequently used to infect BHK cells transfected with the coronavirus receptor indicated.
0.617: (BHK cells; be transfected with; the coronavirus receptor)

Shown are data from 3 replicates.
0.842: (Shown; are data from; 3 replicates)

c, Expression and pseudotype incorporation of SARS-S-2019-nCoV RBD chimeras.
No extractions found.

d, Pseudotypes were used to infect cells expressing hACE2, hDPP4, hAPN, or empty vector, without protease treatment.
0.69: (Pseudotypes; were used hDPP4 , hAPN , or empty vector , without; protease treatment)
0.632: (Pseudotypes; to infect; cells expressing hACE2)
0.629: (Pseudotypes; were used; hDPP4)
0.513: (d; were used hDPP4 , hAPN , or empty vector , without; protease treatment)
0.448: (d; to infect; cells expressing hACE2)
0.445: (d; were used; hDPP4)

a, Schematic overview of clade 1, 2 and 3. Highlighted in yellow are the 14 residues that contact human ACE2.
No extractions found.

Deletions in loops 1 and 2 are indicated for clades 2 and 3. b, Structure of human ACE2 and the SARS-S RBD (PDB: 2AJF), with loops highlighted in gray.
0.9: (Deletions; are indicated for; clades 2 and 3. b)
0.705: (loops; be highlighted in; gray)
0.516: (clades 2 and 3. b; be Structure of; human ACE2 and the SARS-S RBD)

c, VSV pseudotypes were generated with the indicated RBD and used to infect BHKs transfected with either human ACE2 or empty vector.
0.888: (VSV pseudotypes; were generated with; the indicated RBD)
0.8: (c; were generated with; the indicated RBD)
0.695: (BHKs; transfected with; human ACE2 or empty vector)

Shown are data for 3 replicates.
0.842: (Shown; are data for; 3 replicates)

d, Westernblot of producer cell lysates and concentrated pseudotyped particles.
No extractions found.

a, Full length spike sequences from As6526 (clade 2) and BM48-31 (clade 3) were codon optimized, FLAG tagged and synthesized.
No extractions found.

Silent mutations flanking the RBD facilitated replacing the native RBD with the clade 1 consensus RBD.
0.833: (Silent mutations flanking the RBD; facilitated replacing the native RBD with; the clade 1 consensus)
0.741: (Silent mutations flanking the RBD; facilitated replacing; the native RBD)
0.661: (the native RBD; be replacing with; the clade 1 consensus)

b, Westernblot of producer cell lysates and concentrated pseudotypes particles.
No extractions found.

c, Pseudotypes with indicated spike constructs were left untreated or treated with trypsin and subsequently used to infect Huh7.5 cells.
0.917: (Pseudotypes; were left untreated; untreated or treated with trypsin and subsequently)
0.839: (c; were left untreated; untreated or treated with trypsin and subsequently)

Shown are data for 3 replicates.
0.842: (Shown; are data for; 3 replicates)

d, Pseudotypes with indicated spike constructs were left untreated or treated with trypsin and subsequently used to infect BHK cells transfected with human ACE2.
0.67: (BHK cells; be transfected with; human ACE2)
0.583: (Pseudotypes; to infect; BHK cells)

Shown are data for 3 replicates.
0.842: (Shown; are data for; 3 replicates)

